Artificial Skin Market
By Skin Type (Artificial, Natural),
By Application (Chronic Wounds [Venous Leg Ulcer, Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU), Other Chronic Wounds], Acute Wounds [Surgical and Traumatic Wounds, Burn Injuries]),
By Product (Allogenic, Autologous, Xenogeneic, Acellular, Others),
By End Use (Hospitals, Specialty Clinics, Wound Care Centers, Others),
By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa):
Global Analysis and Forecast 2022-2032.
The global Artificial Skin market showcased a revenue of USD 2.3 billion in 2021 and is projected to witness a compounded annual growth rate (CAGR) of more than 15.2% over the forecast period of 2022-2032.
Russia-Ukraine War Impact
Market Scope
About the Market
Impact of COVID-19
Global Economic Slowdown
Market Dynamics
Driver
Restrain
Opportunity
Recent Developments
Synopsis
How is this report helpful
FAQ's
Report Coverage
Related Reports
In place of skin transplants, artificial skin replacements help wounds recover faster. Artificial skin substitutes can be created using the patient's cells or cells from other "allogeneic" (non-self) sources. These skin substitutes consist of an outer epidermal layer and a dermal layer implanted into an acellular matrix. It may also be made from synthetic materials, xenographic tissue, or a combination of these components. Rising rates of obesity and chronic skin illnesses, are accelerating the use of artificial skin. The market for bioengineered artificial skin is anticipated to expand rapidly over the forecast period of 2022-2032. Additionally, rising government funding and aid for research and the expanding popularity of tissue-engineered goods and regenerative medicine support the market's expansion. The strict regulations by the bodies governing the commercialization of skin substitute products pose the biggest obstacle to the market's expansion.
Major factors supporting the lucrative growth rate of the artificial skin market in the forecast period will be accelerating obesity, rising skill illness, and individuals getting more aware of their skin and look, followed by improving purchase power and spending capacities of individuals towards the health and wellness domain. The market for artificial skin is anticipated to expand rapidly over the forecast period of 2022-2032.
Furthermore, artificial skin substitutes have developed gradually over the past few decades, focusing on acute and chronic wounds, including venous leg ulcers, pressure ulcers, and diabetic foot ulcers. To shorten patient stays and lower total wound management costs, emergency rooms, and wound care facilities are increasingly embracing these solutions. Numerous skin substitutes are on the market right now, each with unique applications, advantages, and disadvantages that change based on the clinical situation. Each product, which is created from acellular materials or can be synthesized from autologous, allograft, xenogeneic, or synthetic sources, has advantages. New developments have been made in their redesign and remodeling to improve the usability, commercial viability, and shelf life of the currently available substitutes. Newer techniques are being developed to produce skin substitutes for a wider range of clinical applications as tissue engineering technology advances.
Impact of the Russia-Ukraine War on the Artificial Skin Market
The Russia-Ukraine war has had a notable impact on the artificial skin market. The war has had a significant negative impact on all healthcare industries and the artificial skin industry. The ongoing war has distorted the medical infrastructure of both nations, followed by the limited stock of critical medicines. Doctors in Ukraine are fleeing to other countries, leaving the nation in vulnerable and critical medical conditions. Government officials and doctors who prefer to stay in Ukraine are engaged in critical care units and work around the cloud to aid people injured from war. Such situations have reduced artificial skin requirements while focusing on life-critical requirements.
Artificial Skin: Market Scope
The artificial skin market is primarily divided into four segments skin type, application, product, and end-use. Furthermore, these segments are subdivided into respective categories and cross-referenced to North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa for regional analysis. The skin type segment is divided into artificial and natural. The application segment is categorized into chronic wounds and acute wounds. The chronic wound segmented within the application is further sub-segmented by venous leg ulcers, diabetic foot ulcers (DFU), pressure ulcers (PU), and other chronic wounds. In contrast, acute wounds are sub-segmented by surgical and traumatic wounds and burn injuries. Concerning the product, the artificial skin market is divided into allogenic, autologous, xenogeneic, acellular, and other. The end-user segment encompasses hospitals, specialty clinics, and wound care centers. The historical dataset of value (USD Million) for 2017-2021 is provided in the report, whereas the forecast period of 2022-2032 is offered.
The artificial skin segment will witness the highest growth rate between 2022-2032
Technological advancement in robotics and the medical industry are among the major considerations influencing the market dynamics within the forecast period. Artificial skin is used for human operations and integrating these technologies with humanoid robots to provide touch and feel reflexes are among the major market opportunities. Robotic industry players are actively collaborating with bio-engineering firms for research and development and acquiring artificial skin for robots. For instance, in June 2022, an artificial skin was engineered at Caltech, enabling the user to gather data such as temperature, surface finish, material toxicity, and pressure through direct touch. The skin is designed to be integrated with robot parts, while the sensors are linked to the human operator. Such an innovative approach toward the application of artificial skin will boost business opportunities over the forecast period.
The chronic Wounds segment will witness the highest growth rate between 2022-2032
Acute and chronic wounds fall into two types that can be treated with skin replacements. A chronic wound is one whose wound-healing cycle has been disrupted for various reasons, including decreased angiogenesis, cellular intervention, and innervation. Non-healing wounds, contaminated or infected surgical wounds, pressure ulcers, diabetic foot ulcers, venous leg ulcers, and ischemic ulcers are typical chronic wounds. Acute wounds, in contrast to chronic wounds, are injuries to the skin or deeper tissues that happen suddenly rather than over time. It heals at a predictable and expected rate, in line with how a typical wound heals. Chronic wounds do not heal after six weeks of routine wound treatment. These wounds result from a significant functional impairment, a loss in quality of life, and a significant financial burden on individuals and the healthcare system. However, the underlining clinical profile of chronic wounds hasn't been thoroughly identified and studied due to complicated issues and comorbidities. As a result, these wounds typically take months or years to fully recover. According to estimates, wound management costs in Europe account for 2% to 4% of total healthcare spending. At the same time, studies in the U.S. have estimated wound management expenditures at $25 billion.
The allogenic segment will capture the highest market share within the product segment.
The science of wound care is quickly developing, primarily due to new healing techniques such as stem cell therapy, enhanced dressings, growth factors, and skin replacements. The market for skin substitutes has significantly grown in popularity over the past 20 years, signaling the approval and commercialisation of numerous bioengineered artificial skin products. The widespread use of these products for various therapeutic applications in the wound therapy market has been accelerated by the quick development of synthetic tissues and improvements in biomaterials and tissue engineering. The allogenic materials are frequently utilized in sandwich grafting techniques and definitive dressing wound bed preparation. Skin allografts have been widely utilized to prepare burn wound beds because they aid in boosting wound bed vascularity and promoting capillary development. By applying skin allograft, the newly excised burn wound could be improved and acclimated to get ready for upcoming autografting.
The hospital segment will capture the highest market share in the coming years.
The hospitals will capture the highest market share within the end-use segment of the artificial skin market, backed by the increasing availability of artificial skin across the hospitals. Privatization of the healthcare segment and increasing the spending capacity of patients towards their wound treatment are also the major driving factors. The increasing number of critical injuries followed by an influx of passengers within the hospital segment is a vital factor supporting the business opportunities in the segment. Furthermore, the rapid development of hospital infrastructure across the globe due to COVID-19 has offered the artificial skin market ample business space for penetration.
North America to capture the highest market share in the artificial skin market
In 2021, North America held the biggest market share for artificial skin because of the region's increasingly aging population, increased patient awareness, and rising prevalence of chronic diseases, particularly in the U.S. Due to the increased demand and expanding use of skin replacements in managing chronic wounds, the chronic wound care market segment is expanding quickly. By providing a reliable source of income for the businesses present in this market, this segment is anticipated to propel the growth of the bioengineered skin replacement market. As a result, the prevalence of chronic wounds like diabetic foot ulcers and pressure ulcers has increased, which is the main driver of the market for bioengineered skin substitutes. The healthcare system in the United States is among the most expensive in the world and has the highest standards. A sizable potential population is created by the rising prevalence of chronic wounds like diabetic foot ulcers, venous ulcers, and pressure ulcers (the CDC estimates that approximately 2.5 million patients in the U.S. experience pressure ulcers annually). Furthermore, given that diabetes is more common in Canada than, in other developed countries, a disproportionately high percentage of adults have been diagnosed with the disease and have gone on to receive treatment. In some provinces, this percentage is over 50%
Impact of COVID-19 on the Artificial Skin Industry
COVID-19 had a notable impact on the healthcare industry, rippling the effect on the artificial skin market. The COVID-19 pandemic has demonstrated how flaws in health systems can significantly impact people's health, ability to advance economically, confidence in governments, and social cohesiveness. The shift in allocation towards emergency medical resources and supply demonstrated an acute financial crunch within the artificial skin segment. Companies and government bodies worldwide were reallocating their resources toward critical services from other domains, such as research and development. Furthermore, limited trade, travel, and transaction followed by the global lockdown have also negatively impacted the artificial skin industry.
Artificial Skin: Market Dynamics
The market dynamics section of the report covers a depth analysis of drivers' restraints and opportunities impacting the artificial skin market. The report also encompasses major market strategies practiced by the industry, followed by patent analysis, product analysis, competitive benchmarking of companies, PORTER and PESTLE analysis of the artificial skin industry, pricing analysis, and geographic competitiveness to provide a detailed understanding. The major players operating the market are AbbVie Inc, Anika Therapeutics, Inc., Aroa Biosurgery Limited, Boston Scientific Corporation, Integra LifeSciences Corporation, Organogenesis Inc., Smith & Nephew plc, Stryker Corporation, Vericel Corporation, and Zimmer Biomet Holdings, Inc. These companies cumulatively hold most of the artificial skin market share and actively undergo strategic development, such as new product launches, mergers, collaborations, business expansion, acquisitions, and long-term contracts to ensure market penetration. These companies also largely focus on research and development to gain technological competitiveness in the market. A detailed analysis of these companies is offered in the report.
Driver: Increasing incidents of chronic wounds and critical injuries
Chronic wounds are a major burden on the world's healthcare system and greatly impact the market expansion for bioengineered skin substitutes. The global burden of illness survey from 2013 found that skin and subcutaneous disorders were still the world's most common cause of nonfatal disease and contributed roughly 1.79% to the global disease burden. According to the World Health Organization, there are around 132,000 cases of melanoma skin cancer per year. Thus, the increased prevalence of chronic diseases raises the need for skin substitutes, a major driver driving the market's expansion. Chronic wounds primarily include venous leg ulcers, pressure ulcers, and diabetic foot ulcers. In the hospital context, pressure ulcer prevalence ranged from 1.1% to 26.7%; in the community, it ranged from 6% to 29%; in nursing homes, it ranged from 7.6% to 53.2%; and in intensive care units (ICU), it ranged from 13.1% to 28.7%. The prevalence of venous ulcers in the community ranged from 0.05% to 1%, according to about eight research studies (derived from Medline, EMBASE, CINAHL, and Cochrane Library) in six countries. According to two studies, the yearly period prevalence in the population was 1.69% and ranged from 0.26% to 1.48%. According to estimates, the prevalence was 2.5% in nursing homes and 0.05% in hospitals.
Restrain the High cost of treatment and unclear regulatory landscape at the global level.
The initial therapy is fairly expensive, but the entire cost of the treatment over time is far lower than with standard treatments. In contrast to cadaver skin, which costs between $600 and $800 per square foot, skin grafts typically cost around $3,600. AlloDerm and Integra, two popular products on the market for bioengineered skin substitutes, have prices that range from 15 to 30 USD per square centimeter to give you an idea of how much skin substitutes generally cost. Additionally, the prices for TransCyte, DermaMatrix, and Apligraf can all be up to four times as costly. Furthermore, several regulatory organizations, including the FDA, WHO, International Organization for Standardization (ISO), American Society for Testing and Materials (ASTM), and Consumer Data Rights (CDR), have established several rules for quality checks and pre-market approvals of the products before they are tested on human subjects. For instance, in the United States, the Center for Devices and Radiological Health (CDRH), the Center for Drug Evaluation and Research (CDER), and the Center for Biologic Evaluation and Research (CBER) must examine and approve any medical device marketing before it can be done legally. Each nation has a regulatory agency, and businesses operating there must follow its rules. Therefore, it is difficult to create skin substitutes with these requirements.
Opportunity: Increasing awareness about the usage of artificial skin treatments
According to the list of the world's major economies, China is the largest, and India is the third. The standard of living has improved due to economic expansion in the nations. The general public is becoming more aware of patients' needs, and they are also becoming more self-aware of their bodies, skin, and health. As people become more aware of the need for biomaterials, there has also been a growth in the frequency of routine medical exams and operations. Growing economies in these nations provide several prospects for the worldwide bioengineered skin replacements market as improved lifestyles and increased knowledge of such surgeries result.
Artificial Skin Market: Recent Developments
- In July 2022, Eindhoven University of Technology demonstrated an artificial skin callable of sweating. Such skin type, capable of secreting fluid, has a range of application opportunities that the university will explore over the years.
- In July 2021, Stanford University researchers introduced a transistor array that can be printed on a skin-like material and folded, stretched, or twisted like artificial skin. The circuits can be integrated with the human body, enabling endless IoT possibilities.
- In December 2020, a team of researchers at RMIT University, Australia, developed an artificial skin capable of sensing pain. Researchers aim to develop an artificial skin capable of triggering pain-avoiding reactions.
Artificial Skin Market: Synopsis
The study of the artificial skin market offers revenue and growth data sets in terms of value for segments provided at the global, regional, and country levels. The report offers the historical data set for 2017-2021 and the forecast period of 2022-2032. For analysis, Quadrant Market Insights (QMI) has segregated the artificial skin market into four major segments as follows:
By Skin Type
- Artificial
- Natural
By Application
- Chronic Wounds
- Venous Leg Ulcer
- Diabetic Foot Ulcer (DFU)
- Pressure Ulcer (PU)
- Other Chronic Wounds - Acute Wounds
- Surgical and Traumatic Wounds
- Burn Injuries
By Product
- Allogenic
- Autologous
- Xenogeneic
- Acellular
- Others
By End Use
- Hospitals
- Speciality Clinics
- Wound Care Centers
- Others
The regional analysis of the artificial skin market is as follows:
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Russia
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
Latin America
- Brazil
- Mexico
- Argentina
- Chile
Middle East & Africa
- South Africa
- UAE
- Saudi Arabia
- Israel
Key players operating in the artificial skin industry are:
- AbbVie Inc
- Anika Therapeutics, Inc.
- Aroa Biosurgery Limited
- Boston Scientific Corporation
- Integra LifeSciences Corporation
- Organogenesis Inc.
- Smith & Nephew plc
- Stryker Corporation
- Vericel Corporation
- Zimmer Biomet Holdings, Inc.
Artificial Skin Market: Who Should Purchase, and How It Will Help Readers
- The report is best suited for top-level decision-makers, individuals who are supposed to take a leadership role or require market research to start a business, independent researchers, research institutes, and anyone who wishes to gain detailed strategic insights into the artificial skin market.
- This report provides a qualitative and quantitative analysis of the market segments, current trends, estimations, and dynamics of the artificial skin market analysis from 2017 to 2032 to identify the prevailing market opportunities.
- Market research and information related to key drivers, restraints, and opportunities are offered.
- Porter's five forces and PESTLE analysis highlight the potency of buyers and suppliers to enable stakeholders' market profit-oriented business decisions and strengthen their supplier-buyer network.
- An in-depth analysis of the artificial skin market segmentation assists in determining the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes an analysis of the regional and global artificial skin industry trends, key players, market segments, application areas, and market growth strategies.
- The report offers insights from primary interviews and CXOs of major industry players. It also offers a comprehensive contact and event repository to ensure future collaborations among industry stakeholders.
Artificial Skin Market: Frequently Asked Questions (FAQ)
Q: How big is the Artificial Skin market?
A: The global Artificial Skin market showcased a revenue of USD 2.3 billion in 2021 and is projected to witness a compounded annual growth rate (CAGR) of more than 15.2% over the forecast period of 2022-2032.
Q: Does the report have several artificial skins bifurcated by segments and regions?
A: The report offers a total number of artificial skin, further bifurcated into segments and regions. Please refer to the TOC page for more information.
Q: What are the major trends in the artificial skin market?
A: The rise in awareness from the consumer end about various usage and benefits of artificial skin, followed by increasing research and development by major industry players across the globe, are major trends expected to shape the market opportunities over the coming years.
Q: How can I get the sample Report on the artificial skin market?
A: The artificial skin market report sample can be obtained on demand from the website. Also, 24*7 chat support and direct call services are provided to procure the sample report
Q: Is it possible to purchase a specific or customized report as per my needs
A: Yes, it is possible to purchase a specific part of the report or edit the scope of the report at your convenience. Feel free to drop us the mail/talk to our customer support or schedule a conversation to procure a customized report.
Report Coverage
- Skin Type
- Application
- Product
- End Use
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
- Increasing incidents of chronic wounds and critical injuries
- Increasing awareness about the usage of artificial skin treatments
- High cost of treatment and unclear regulatory landscape at global level
AbbVie Inc, Anika Therapeutics, Inc., Aroa Biosurgery Limited, Boston Scientific Corporation, Integra LifeSciences Corporation, Organogenesis Inc., Smith & Nephew plc, Stryker Corporation, Vericel Corporation, and Zimmer Biomet Holdings, Inc.
1. Introduction
1.1 Report Description
1.1.1 Definition
1.1.2 Abbreviations
1.2 Key Market Segments
1.3 Benefits to Stakeholders
1.4 Research Methodology
1.4.1 Market Scoping
1.4.1.1 Problem Identification
1.4.1.2 Defining the Market
1.4.2 Market Estimation
1.4.2.1 Data Mining
1.4.2.2 Product Analysis
1.4.2.3 Application Analysis
1.4.2.4 Market Engineering and Forecasting
1.4.2.4.1 Bottom-up Demand Side
1.4.2.4.2 Bottom-up Supply side
1.4.3 Market Authentication
1.4.3.1 Data Triangulation
1.4.3.1.1 Top-down Supply Side
1.4.3.1.2 Top-down Demand Side
1.4.3.1.3 Data Triangulation
1.4.3.2 Primary Insights and Industry feedback
1.4.4 Report Writing
2. Executive Summary
2.1 Market Snapshot
2.2 Primary Insights
3. Market Overview
3.1 Market Segment and Scope
3.2 Top Investment Pockets
3.3 Key Strategic Initiatives
3.4 Artificial Skin Market Industry Ecosystem
3.5 Market Evolution
3.6 Patent Analysis
3.7 Technology Landscape
3.8 Regulatory Infrastructure
3.9 Porter’s Analysis
3.9.1 Bargaining Power of Buyer
3.9.2 Bargaining Power of Supplier
3.9.3 Threat of New Entrants
3.9.4 Threat of Substitutes
3.9.5 Industry Rivalry
3.10 PESTLE Analysis
3.11 Market Dynamics
3.11.1 Drivers
3.11.2 Restrains
3.11.3 Opportunities
3.12 Impact of COVID-19 on Artificial Skin Market
3.13 Russia-Ukraine War Impact on Artificial Skin Market
3.14 Growth Share Matrix
3.15 Artificial Skin Market Quadrant
4. Artificial Skin Market, By Skin Type
4.1 Major Impacting Factors, By Skin Type
4.1.1 Key Market Trends and Growth Factors
4.1.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
4.1.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
4.2 Artificial
4.2.1 Key Market Trends and Growth Factors
4.2.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
4.2.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
4.3 Natural
4.3.1 Key Market Trends and Growth Factors
4.3.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
4.3.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
5. Artificial Skin Market, By Application
5.1 Major Impacting Factors, By Application
5.1.1 Key Market Trends and Growth Factors
5.1.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
5.1.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
5.2 Chronic Wounds
5.2.1 Key Market Trends and Growth Factors
5.2.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
5.2.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
5.2.4 Venous Leg Ulcer
5.2.4.1 Key Market Trends and Growth Factors
5.2.4.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
5.2.4.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
5.2.5 Diabetic Foot Ulcer (DFU)
5.2.5.1 Key Market Trends and Growth Factors
5.2.5.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
5.2.5.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
5.2.6 Pressure Ulcer (PU)
5.2.6.1 Key Market Trends and Growth Factors
5.2.6.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
5.2.6.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
5.2.7 Other Chronic Wounds
5.2.7.1 Key Market Trends and Growth Factors
5.2.7.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
5.2.7.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
5.3 Acute Wounds
5.3.1 Key Market Trends and Growth Factors
5.3.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
5.3.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
5.3.4 Surgical and Traumatic Wounds
5.3.4.1 Key Market Trends and Growth Factors
5.3.4.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
5.3.4.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
5.3.5 Burn Injuries
5.3.5.1 Key Market Trends and Growth Factors
5.3.5.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
5.3.5.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
6. Artificial Skin Market, By Product
6.1 Major Impacting Factors, By Product
6.1.1 Key Market Trends and Growth Factors
6.1.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
6.1.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
6.2 Allogenic
6.2.1 Key Market Trends and Growth Factors
6.2.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
6.2.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
6.3 Autologous
6.3.1 Key Market Trends and Growth Factors
6.3.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
6.3.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
6.4 Xenogeneic
6.4.1 Key Market Trends and Growth Factors
6.4.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
6.4.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
6.5 Acellular
6.5.1 Key Market Trends and Growth Factors
6.5.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
6.5.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
6.6 Others
6.6.1 Key Market Trends and Growth Factors
6.6.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
6.6.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
7. Artificial Skin Market, By End Use
7.1 Major Impacting Factors, By End Use
7.1.1 Key Market Trends and Growth Factors
7.1.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
7.1.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
7.2 Hospitals
7.2.1 Key Market Trends and Growth Factors
7.2.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
7.2.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
7.3 Specialty Clinics
7.3.1 Key Market Trends and Growth Factors
7.3.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
7.3.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
7.4 Wound Care Centers
7.4.1 Key Market Trends and Growth Factors
7.4.2 Market Size and Forecast, by Region, 2017-2032, (USD Million)
7.4.3 Market Size and Forecast, by Country, 2017-2032, (USD Million)
8. Artificial Skin Market, By Region
8.1 Global Market Trends and Growth Factors
8.2 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.3 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.3.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.3.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.4 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.5 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.6 Market Size and Forecast, by Region, 2017-2032, (USD Million)
8.7 North America
8.7.1 Key Market Trends and Growth Factors
8.7.2 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.7.3 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.7.3.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.7.3.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.7.4 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.7.5 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.7.6 Market Size and Forecast, by Country, 2017-2032, (USD Million)
8.7.7 U.S.
8.7.7.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.7.7.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.7.7.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.7.7.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.7.7.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.7.7.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.7.8 Canada
8.7.8.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.7.8.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.7.8.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.7.8.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.7.8.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.7.8.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.7.9 Mexico
8.7.9.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.7.9.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.7.9.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.7.9.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.7.9.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.7.9.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.8 Europe
8.8.1 Key Market Trends and Growth Factors
8.8.2 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.8.3 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.8.3.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.8.3.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.8.4 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.8.5 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.8.6 Market Size and Forecast, by Country, 2017-2032, (USD Million)
8.8.7 UK
8.8.7.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.8.7.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.8.7.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.8.7.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.8.7.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.8.7.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.8.8 Germany
8.8.8.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.8.8.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.8.8.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.8.8.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.8.8.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.8.8.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.8.9 France
8.8.9.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.8.9.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.8.9.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.8.9.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.8.9.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.8.9.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.8.10 Russia
8.8.10.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.8.10.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.8.10.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.8.10.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.8.10.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.8.10.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.8.11 Italy
8.8.11.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.8.11.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.8.11.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.8.11.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.8.11.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.8.11.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.8.12 Rest of Europe
8.8.12.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.8.12.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.8.12.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.8.12.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.8.12.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.8.12.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.9 Asia-Pacific
8.9.1 Key Market Trends and Growth Factors
8.9.2 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.9.3 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.9.3.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.9.3.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.9.4 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.9.5 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.9.6 Market Size and Forecast, by Country, 2017-2032, (USD Million)
8.9.7 China
8.9.7.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.9.7.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.9.7.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.9.7.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.9.7.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.9.7.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.9.8 India
8.9.8.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.9.8.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.9.8.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.9.8.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.9.8.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.9.8.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.9.9 Japan
8.9.9.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.9.9.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.9.9.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.9.9.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.9.9.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.9.9.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.9.10 Australia
8.9.10.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.9.10.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.9.10.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.9.10.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.9.10.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.9.10.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.9.11 Rest of Asia-Pacific
8.9.11.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.9.11.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.9.11.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.9.11.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.9.11.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.9.11.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.10 Latin America
8.10.1 Key Market Trends and Growth Factors
8.10.2 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.10.3 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.10.3.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.10.3.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.10.4 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.10.5 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.10.6 Market Size and Forecast, by Country, 2017-2032, (USD Million)
8.10.7 Brazil
8.10.7.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.10.7.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.10.7.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.10.7.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.10.7.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.10.7.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.10.8 Argentina
8.10.8.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.10.8.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.10.8.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.10.8.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.10.8.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.10.8.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.10.9 Mexico
8.10.9.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.10.9.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.10.9.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.10.9.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.10.9.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.10.9.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.10.10 Chile
8.10.10.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.10.10.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.10.10.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.10.10.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.10.10.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.10.10.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.11 Middle East and Africa
8.11.1 Key Market Trends and Growth Factors
8.11.2 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.11.3 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.11.3.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.11.3.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.11.4 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.11.5 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.11.6 Market Size and Forecast, by Country, 2017-2032, (USD Million)
8.11.7 South Africa
8.11.7.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.11.7.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.11.7.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.11.7.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.11.7.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.11.7.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.11.8 UAE
8.11.8.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.11.8.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.11.8.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.11.8.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.11.8.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.11.8.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.11.9 Saudi Arabia
8.11.9.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.11.9.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.11.9.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.11.9.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.11.9.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.11.9.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
8.11.10 Israel
8.11.10.1 Market Size and Forecast, by Skin Type, 2017-2032, (USD Million)
8.11.10.2 Market Size and Forecast, by Application, 2017-2032, (USD Million)
8.11.10.2.1 Market Size and Forecast, by Chronic Wounds , 2017-2032, (USD Million)
8.11.10.2.2 Market Size and Forecast, by Acute Wounds , 2017-2032, (USD Million)
8.11.10.3 Market Size and Forecast, by Product, 2017-2032, (USD Million)
8.11.10.4 Market Size and Forecast, by End Use, 2017-2032, (USD Million)
9. Markets-Competitive Benchmarking & Company Profiles
9.1 Competitive Benchmarking
9.1.1 Company Market Share
9.1.2 Product Mapping
9.1.3 Competitive Heat map
9.2 AbbVie Inc
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Product Offering
9.2.4 Strategic Initiatives
9.2.5 SWOT
9.2.6 Ansoff Matrix
9.3 Anika Therapeutics, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Product Offering
9.3.4 Strategic Initiatives
9.3.5 SWOT
9.3.6 Ansoff Matrix
9.4 Aroa Biosurgery Limited
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Product Offering
9.4.4 Strategic Initiatives
9.4.5 SWOT
9.4.6 Ansoff Matrix
9.5 Boston Scientific Corporation
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Product Offering
9.5.4 Strategic Initiatives
9.5.5 SWOT
9.5.6 Ansoff Matrix
9.6 Integra LifeSciences Corporation
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Product Offering
9.6.4 Strategic Initiatives
9.6.5 SWOT
9.6.6 Ansoff Matrix
9.7 Organogenesis Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Product Offering
9.7.4 Strategic Initiatives
9.7.5 SWOT
9.7.6 Ansoff Matrix
9.8 Smith & Nephew plc
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Product Offering
9.8.4 Strategic Initiatives
9.8.5 SWOT
9.8.6 Ansoff Matrix
9.9 Stryker Corporation
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Product Offering
9.9.4 Strategic Initiatives
9.9.5 SWOT
9.9.6 Ansoff Matrix
9.10 Vericel Corporation
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Product Offering
9.10.4 Strategic Initiatives
9.10.5 SWOT
9.10.6 Ansoff Matrix
9.11 Zimmer Biomet Holdings, Inc.
9.11.1 Company Overview
9.11.2 Financial Analysis
9.11.3 Product Offering
9.11.4 Strategic Initiatives
9.11.5 SWOT
9.11.6 Ansoff Matrix
10. Industry Connects and Seminars
